Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial

Eugene McLaurin, Megan E Cavet, Paul J Gomes, Joseph B Ciolino, Eugene McLaurin, Megan E Cavet, Paul J Gomes, Joseph B Ciolino

Abstract

Significance: The α2-adrenergic receptor agonist brimonidine has been reported to induce conjunctival blanching in cataract, strabismus, laser refractive, and filtration procedures. Clinicians are often faced with red eyes with no apparent underlying pathology. Low-dose brimonidine reduced ocular redness in such subjects with efficacy maintained over 1 month and negligible rebound redness.

Purpose: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for the treatment of ocular redness.

Methods: In this single-center, double-masked, phase 3 clinical trial, adult subjects with baseline redness of more than 1 unit in both eyes (0- to 4-unit scale) were randomized 2:1 to brimonidine 0.025% or vehicle. A single dose was administered in-office (day 1); thereafter subjects instilled treatment four times a day for 4 weeks, with clinic visits on days 15, 29, and 36 (7 days post-treatment). Efficacy end points included investigator-evaluated redness 5 to 240 minutes post-instillation on day 1 (primary); investigator-evaluated change from baseline 1, 360, and 480 minutes post-instillation on day 1, and 1 and 5 minutes post-instillation on days 15 and 29; total clearance of redness, and subject-assessed redness. Safety/tolerability measures included adverse events, rebound redness, and drop comfort.

Results: Sixty subjects were randomized (n = 40 brimonidine, n = 20 vehicle). Investigator-assessed redness was lower with brimonidine versus vehicle over the 5- to 240-minute post-instillation period (mean [SE], 0.62 [0.076] vs. 1.49 [0.108]; P < .0001) and at each time point within that period (P < .0001). At 1, 360, and 480 minutes post-instillation, respectively, the mean differences (95% confidence interval) between treatments were -0.73 (-1.05 to -0.41), -0.57 (-0.84 to -0.29), and -0.39 (-0.67 to -0.10), respectively. No tachyphylaxis was evident with brimonidine on days 15 and 29, and minimal rebound redness was observed following discontinuation. Adverse events were infrequent, and brimonidine was rated as very comfortable.

Conclusions: Brimonidine 0.025% appeared safe and effective for reduction of ocular redness, with an 8-hour duration of action, no evidence of tachyphylaxis, and negligible rebound redness.

Trial registration: ClinicalTrials.gov NCT01959230.

Conflict of interest statement

Conflict of Interest Disclosure: EM has received research grants from the following companies: Aciex, Acucela, Alcon Research Ltd., Allergan, AstraZeneca, Bausch + Lomb, Inotek Pharma, InSite Vision, Lexicon Pharma, Mimetogen, and Ocular Therapeutix. MEC is an employee of Bausch + Lomb. PJG is an employee of Ora. JBC is a paid consultant for Ora.

Figures

FIGURE 1
FIGURE 1
Investigator-evaluated ocular redness (0- to 4-unit scale) at day 1 by treatment in the intent-to-treat (ITT) population. Data are means (SE); *P < .0001 vs. vehicle at the indicated time point (last observation carried forward); #P ≤ 0.01 vs. vehicle at the indicated time point (observed data only).
FIGURE 2
FIGURE 2
Subject-graded ocular redness (0- to 4-unit scale) over the whole treatment period by treatment in the intent-to-treat population with observed data only. Data are means (SE).
FIGURE 3
FIGURE 3
Photographs from a representative eye with baseline ocular redness graded as moderate (score of 2) before (A) and 5 minutes after (B) instillation of one drop of brimonidine tartrate ophthalmic solution 0.025% (score of 0 or none).
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5839712/bin/opx-95-264-g001.jpg

References

    1. Cronau H, Kankanala RR, Mauger T. Diagnosis and Management of Red Eye in Primary Care. Am Fam Physician 2010;81:137–44.
    1. Galor A, Jeng BH. Red Eye for the Internist: when to Treat, when to Refer. Cleve Clin J Med 2008;75:137–44.
    1. Bartels SP. Adrenergic agents. In: Albert DM, Jakobiec FA, eds. Principals and Practices of Ophthalmology, Basic Sciences, Philadelphia, PA: W. B. Saunders Company; 1994;993–1012.
    1. Stafford-Smith M, Bartz R, Wilson K, et al. Alpha-adrenergic mRNA Subtype Expression in the Human Nasal Turbinate. Can J Anaesth 2007;54:549–55.
    1. Soparkar CN, Wilhelmus KR, Koch DD, et al. Acute and Chronic Conjunctivitis Due to Over-the-counter Ophthalmic Decongestants. Arch Ophthalmol 1997;115:34–8.
    1. Spector SL, Raizman MB. Conjunctivitis Medicamentosa. J Allergy Clin Immunol 1994;94:134–6.
    1. Tappeiner C, Sarra GM, Abegg M. Abuse of Vasoconstrictive Eyedrops Mimicking an Ocular Pemphigoid. Eur J Ophthalmol 2009;19:129–32.
    1. Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of Response and Rebound Congestion. Am J Respir Crit Care Med 2010;182:19–24.
    1. Fratelli M, De Blasi A. Agonist-induced Alpha 1-Adrenergic Receptor Changes. Evidence for Receptor Sequestration. FEBS Lett 1987;212:149–53.
    1. Insel PA. Seminars in Medicine of the Beth Israel Hospital, Boston. Adrenergic Receptors—Evolving Concepts and Clinical Implications. N Engl J Med 1996;334:580–5.
    1. Guimaraes S, Moura D. Vascular Adrenoceptors: An Update. Pharmacol Rev 2001;53:319–56.
    1. Adkins JC, Balfour JA. Brimonidine. A Review of Its Pharmacological Properties and Clinical Potential in the Management of Open-angle Glaucoma and Ocular Hypertension. Drugs Aging 1998;12:225–41.
    1. Fudemberg SJ, Batiste C, Katz LJ. Efficacy, Safety, and Current Applications of Brimonidine. Expert Opin Drug Saf 2008;7:795–9.
    1. Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for Glaucoma. Expert Opin Drug Saf 2010;9:483–91.
    1. Crosson CE, Heath AR, DeVries GW, et al. Pharmacological Evidence for Heterogeneity of Ocular Alpha 2 Adrenoceptors. Curr Eye Res 1992;11:963–70.
    1. Potter DE, Crosson CE, Heath AR, et al. Review: Alpha 2 and Da2 Agonists as Antiglaucoma Agents: Comparative Pharmacology and Clinical Potential. J Ocul Pharmacol 1990;6:251–7.
    1. Tong LX, Moore AY. Brimonidine Tartrate for the Treatment of Facial Flushing and Erythema in Rosacea. Expert Rev Clin Pharmacol 2014;7:567–77.
    1. Corboz MR, Mutter JC, Rivelli MA, et al. Alpha2-adrenoceptor Agonists as Nasal Decongestants. Pulm Pharmacol Ther 2007;20:149–56.
    1. Corboz MR, Rivelli MA, Mingo GG, et al. Mechanism of Decongestant Activity of Alpha 2-adrenoceptor Agonists. Pulm Pharmacol Ther 2008;21:449–54.
    1. Melamed S, David R. Ongoing Clinical Assessment of the Safety Profile and Efficacy of Brimonidine Compared with Timolol: Year-three Results. Brimonidine Study Group II. Clin Ther 2000;22:103–11.
    1. Schuman JS, Horwitz B, Choplin NT, et al. A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular Hypertension. A Controlled, Randomized, Multicenter Clinical Trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115:847–52.
    1. Dahlmann-Noor AH, Cosgrave E, Lowe S, et al. Brimonidine and Apraclonidine as Vasoconstrictors in Adjustable Strabismus Surgery. J AAPOS 2009;13:123–6.
    1. Derick RJ, Robin AL, Walters TR, et al. Brimonidine Tartrate: A One-month Dose Response Study. Ophthalmology 1997;104:131–6.
    1. Desco MC, Navea A, Ferrer E, et al. Effect of Prophylactic Brimonidine on Bleeding Complications After Cataract Surgery. Eur J Ophthalmol 2005;15:228–32.
    1. Gupta A, Kekunnaya R, Sachdeva V, et al. Strabismus Surgery Hemostasis. Ophthalmology 2012;119:649–50.
    1. Hong S, Kim CY, Seong GJ, et al. Effect of Prophylactic Brimonidine Instillation on Bleeding during Strabismus Surgery in Adults. Am J Ophthalmol 2007;144:469–70.
    1. Kim CS, Nam KY, Kim JY. Effect of Prophylactic Topical Brimonidine (0.15%) Administration on the Development of Subconjunctival Hemorrhage After Intravitreal Injection. Retina 2011;31:389–92.
    1. Norden RA. Effect of Prophylactic Brimonidine on Bleeding Complications and Flap Adherence After Laser in Situ Keratomileusis. J Refract Surg 2002;18:468–71.
    1. Pasquali TA, Aufderheide A, Brinton JP, et al. Dilute Brimonidine to Improve Patient Comfort and Subconjunctival Hemorrhage After LASIK. J Refract Surg 2013;29:469–75.
    1. Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical Efficacy of Olopatadine Hydrochloride Ophthalmic Solution 0.2% Compared with Placebo in Patients with Allergic Conjunctivitis or Rhinoconjunctivitis: A Randomized, Double-masked Environmental Study. Clin Ther 2004;26:1237–48.
    1. Katz LJ. Brimonidine Tartrate 0.2% Twice Daily vs Timolol 0.5% Twice Daily: 1-Year Results in Glaucoma Patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20–6.
    1. LeBlanc RP. Twelve-month Results of an Ongoing Randomized Trial Comparing Brimonidine Tartrate 0.2% and Timolol 0.5% Given Twice Daily in Patients with Glaucoma or Ocular Hypertension. Brimonidine Study Group 2. Ophthalmology 1998;105:1960–7.
    1. Kim CY, Hong S, Seong GJ. Brimonidine 0.2% Versus Brimonidine Purite 0.15% in Asian Ocular Hypertension. J Ocul Pharmacol Ther 2007;23:481–6.
    1. Katz LJ. Twelve-month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients with Glaucoma or Ocular Hypertension. J Glaucoma 2002;11:119–26.
    1. Ishikawa H, Miller DD, Patil PN. Comparison of Post-junctional Alpha-adrenoceptors in Iris Dilator Muscle of Humans, and Albino and Pigmented Rabbits. Naunyn Schmiedebergs Arch Pharmacol 1996;354:765–72.
    1. Burke J, Schwartz M. Preclinical Evaluation of Brimonidine. Surv Ophthalmol 1996;41(Suppl. 1):S9–18.
    1. Kesler A, Shemesh G, Rothkoff L, et al. Effect of Brimonidine Tartrate 0.2% Ophthalmic Solution on Pupil Size. J Cataract Refract Surg 2004;30:1707–10.
    1. McDonald JE, 2nd, El-Moatassem Kotb AM, Decker BB. Effect of Brimonidine Tartrate Ophthalmic Solution 0.2% on Pupil Size in Normal Eyes under Different Luminance Conditions. J Cataract Refract Surg 2001;27:560–4.
    1. Thordsen JE, Bower KS, Warren BB, et al. Miotic Effect of Brimonidine Tartrate 0.15% Ophthalmic Solution in Normal Eyes. J Cataract Refract Surg 2004;30:1702–6.
    1. Cantor LB. The Evolving Pharmacotherapeutic Profile of Brimonidine, an Alpha 2-Adrenergic Agonist, After Four Years of Continuous Use. Expert Opin Pharmacother 2000;1:815–34.
    1. Lee DA, Gornbein J, Abrams C. The Effectiveness and Safety of Brimonidine as Mono-, Combination, or Replacement Therapy for Patients with Primary Open-angle Glaucoma or Ocular Hypertension: A Post Hoc Analysis of an Open-label Community Trial. Glaucoma Trial Study Group. J Ocul Pharmacol Ther 2000;16:3–18.
    1. Enyedi LB, Freedman SF. Safety and Efficacy of Brimonidine in Children with Glaucoma. J AAPOS 2001;5:281–4.
    1. Bowman RJ, Cope J, Nischal KK. Ocular and Systemic Side Effects of Brimonidine 0.2% Eye Drops (Alphagan) in Children. Eye (Lond) 2004;18:24–6.
    1. Breakey AS, Cinotti AA, Hirshman M. A Double-blind, Multi-centre Controlled Trial of 0.25% Oxymetazoline Ophthalmic Solution in Patients with Allergic and Non-infectious Conjunctivitis. Pharmatherapeutica 1980;2:353–6.
    1. Duzman E, Anderson J, Vita JB, et al. Topically Applied Oxymetazoline. Ocular Vasoconstrictive Activity, Pharmacokinetics, and Metabolism. Arch Ophthalmol 1983;101:1122–6.
    1. Duzman E, Warman A, Warman R. Efficacy and Safety of Topical Oxymetazoline in Treating Allergic and Environmental Conjunctivitis. Ann Ophthalmol 1986;18:28–31.
    1. Rybiczka R, Mauracher E. Oxymetazoline Ophthalmic Solution Versus Naphazoline Solution in Non-infectious Conjunctivitis. Pharmatherapeutica 1983;3:376–81.
    1. Fowler J, Jr., Jackson M, Moore A, et al. Efficacy and Safety of Once-daily Topical Brimonidine Tartrate Gel 0.5% for the Treatment of Moderate to Severe Facial Erythema of Rosacea: Results of Two Randomized, Double-blind, and Vehicle-controlled Pivotal Studies. J Drugs Dermatol 2013;12:650–6.
    1. Moore A, Kempers S, Murakawa G, et al. Long-term Safety and Efficacy of Once-daily Topical Brimonidine Tartrate Gel 0.5% for the Treatment of Moderate to Severe Facial Erythema of Rosacea: Results of a 1-Year Open-label Study. J Drugs Dermatol 2014;13:56–61.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere